New Jersey 2022-2023 Regular Session

New Jersey Assembly Bill AR71

Introduced
2/7/22  

Caption

Promotes increased public awareness about Stargardt's Disease.

Impact

The resolution highlights the critical aspects of Stargardt's Disease, including its genetic transmission and symptoms such as blurry vision and difficulties in adjusting to lighting changes. Given that it affects approximately one in 10,000 children in the U.S., the need for public engagement in understanding such a serious health concern is emphasized. While there are no known cures, ongoing research could provide insights into potential treatment options, making awareness essential for early diagnosis and intervention.

Summary

Assembly Resolution No. 71 (AR71) aims to promote increased public awareness about Stargardt's Disease, which is the most common form of inherited juvenile macular degeneration, causing vision loss primarily in children. The resolution acknowledges the significance of understanding this disease, its genetic basis, and the need for public education regarding its implications. By urging the Governor to take action, the bill seeks to enhance recognition and understanding of the condition, which significantly impacts the lives of those affected by it.

Statement

The resolution further calls upon public officials and citizens to initiate activities and programs that improve awareness and understanding of the disease. Given societal implications, including the ability to maintain independence and carry out daily activities, the underlying message promotes a collective effort to support affected families and individuals in educational contexts and healthcare practices.

Contention

One notable point conveyed through AR71 is the importance of genetic counseling and testing for families with a history of Stargardt's Disease. By subjecting affected families to genetic testing, there can be better personal and familial management of the condition. Additionally, the recognition of devices and services available to aid those impacted by the disease partakes in fostering a supportive environment for individuals and families dealing with vision impairment caused by Stargardt's.

Companion Bills

No companion bills found.

Previously Filed As

NJ HR349

Recognizing the month of April 2024 as "Retinal Blindness Awareness Month" in Pennsylvania.

NJ ACR28

Sickle Cell Disease Awareness Month.

NJ ACR110

Sickle Cell Disease Awareness Month.

NJ AJR91

Designates September 7 through 13 of each year as "Duchenne Muscular Dystrophy Awareness Week" in New Jersey.

NJ HR1784

Promoting greater public awareness of hemophilia and von Willebrand disease.

NJ SCR73

Blue Light Awareness Day.

NJ SJR25

Batten Disease Awareness Weekend.

NJ HR514

Expressing support for the designation of June 19, 2023, as "World Sickle Cell Awareness Day" in order to increase public alertness across the United States and global community about sickle cell disease, the continued need for empirical research, early detection screenings for sickle cell trait carriers, novel effective treatments leading to a cure, and preventative care programs with respect to complications from sickle cell anemia and conditions related to sickle cell disease.

NJ SR255

A resolution expressing support for the designation of June 19, 2023, as "World Sickle Cell Awareness Day" in order to increase public awareness across the United States and global community about sickle cell disease and the continued need for empirical research, early detection screenings, novel effective treatments leading to a cure, and preventative care programs with respect to complications from sickle cell anemia and conditions relating to sickle cell disease.

NJ SR292

A resolution expressing support for the designation of June 19, 2025, as "World Sickle Cell Awareness Day" in order to increase public awareness across the United States and global community about sickle cell disease and the continued need for empirical research, early detection screenings, novel effective treatments leading to a cure, and preventative care programs with respect to complications from sickle cell anemia and conditions relating to sickle cell disease.

Similar Bills

CA SB934

California Childhood Cancer Research Fund Act.

CA AB1103

Controlled substances: research.

CA SB639

Medical professionals: course requirements.

DC PR25-0763

Racial Equity Advisory Board Kimberly Jeffries Leonard Confirmation Resolution of 2024

NJ A2653

Prohibits using cadaveric fetal tissue obtained from elective abortion procedure for research purposes and using any cadaveric fetal tissue to research cosmetic treatments.

NJ A2076

Prohibits using cadaveric fetal tissue obtained from elective abortion procedure for research purposes and using any cadaveric fetal tissue to research cosmetic treatments.

CA AB703

California Pediatric Cancer Research Voluntary Tax Contribution Fund.

FL H1347

Cancer Treatment and Research